Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Hepatocellular Carcinoma | Research

Hsa_circ_0005397 promotes hepatocellular carcinoma progression through EIF4A3

Authors: Liu-Xia Yuan, Mei Luo, Ruo-Yu Liu, Hui-Xuan Wang, Lin-Ling Ju, Feng Wang, Ya-Li Cao, Zhong-Cheng Wang, Lin Chen

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Purpose

The purpose of this study was to explore the expression and potential mechanism of hsa_circ_0005397 in hepatocellular carcinoma progression.

Methods

Quantitative reverse transcription-polymerase chain reaction(qRT-PCR) was used to measure the expression level of hsa_circ_0005397 and EIF4A3 from paired HCC tissues and cell lines. Western Blot (WB) and immunohistochemistry (IHC) were used to verify the protein level of EIF4A3. The specificity of primers was confirmed by agarose gel electrophoresis. Receiver Operating Characteristic (ROC) Curve was drawn to analyze diagnostic value. Actinomycin D and nuclear and cytoplasmic extraction assays were utilized to evaluate the characteristics of hsa_circ_0005397. Cell Counting kit-8 (CCK-8) and colony formation assays were performed to detect cell proliferation. Flow cytometry analysis was used to detect the cell cycle. Transwell assay was performed to determine migration and invasion ability. RNA-binding proteins (RBPs) of hsa_circ_0005397 in HCC were explored using bioinformatics websites. The relationship between hsa_circ_0005397 and Eukaryotic Translation Initiation Factor 4A3 (EIF4A3) was verified by RNA Binding Protein Immunoprecipitation (RIP) assays, correlation and rescue experiments.

Results

In this study, hsa_circ_0005397 was found to be significantly upregulated in HCC, and the good diagnostic sensitivity and specificity shown a potential diagnostic capability. Upregulated expression of hsa_circ_0005397 was significantly related to tumor size and stage. Hsa_circ_0005397 was circular structure which more stable than liner mRNA, and mostly distributed in the cytoplasm. Upregulation of hsa_circ_0005397 generally resulted in stronger proliferative ability, clonality, and metastatic potency of HCC cells; its downregulation yielded the opposite results. EIF4A3 is an RNA-binding protein of hsa_circ_0005397, which overexpressed in paired HCC tissues and cell lines. In addition, expression of hsa_circ_0005397 decreased equally when EIF4A3 was depleted. RIP assays and correlation assay estimated that EIF4A3 could interacted with hsa_circ_0005397. Knockdown of EIF4A3 could reverse hsa_circ_0005397 function in HCC progression.

Conclusions

Hsa_circ_0005397 promotes progression of hepatocellular carcinoma through EIF4A3. These research findings may provide novel clinical value for hepatocellular carcinoma.
Appendix
Available only for authorised users
Literature
1.
Yang B, Zhao J, Huo T, Zhang M, Wu X. Effects of CircRNA-ITCH on proliferation and apoptosis of hepatocellular carcinoma cells through inhibiting Wnt/beta-catenin signaling pathway. J BUON. 2020;25(3):1368–74.PubMed
2.
Cedric BC, Souraka TDM, Feng YL, Kisembo P, Tu JC. CircRNA ZFR stimulates the proliferation of hepatocellular carcinoma through upregulating MAP2K1. Eur Rev Med Pharmacol Sci. 2020;24(19):9924–31.PubMed
3.
Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: review of Epidemiology, Screening, Imaging diagnosis, Response Assessment, and treatment. Curr Probl Diagn Radiol. 2015;44(6):479–86.CrossRefPubMed
4.
Fu PY, Hu B, Ma XL, Tang WG, Yang ZF, Sun HX, Yu MC, Huang A, Hu JW, Zhou CH, et al. Far upstream element-binding protein 1 facilitates hepatocellular carcinoma invasion and metastasis. Carcinogenesis. 2020;41(7):950–60.CrossRefPubMed
5.
Guo XL, Wang HB, Yong JK, Zhong J, Li QH. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1. Eur Rev Med Pharmacol Sci. 2018;22(20):6667–77.PubMed
6.
Liu R, Li Y, Wu A, Kong M, Ding W, Hu Z, Chen L, Cai W, Wang F. Identification of plasma hsa_circ_0005397 and combined with serum AFP, AFP-L3 as potential biomarkers for Hepatocellular Carcinoma. Front Pharmacol. 2021;12:639963.CrossRefPubMedPubMedCentral
7.
Tang X, Ren H, Guo M, Qian J, Yang Y, Gu C. Review on circular RNAs and new insights into their roles in cancer. Comput Struct Biotechnol J. 2021;19:910–28.CrossRefPubMedPubMedCentral
8.
Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, Xue W, Cui Y, Dong K, Ding H, et al. Structure and degradation of circular RNAs regulate PKR activation in Innate Immunity. Cell. 2019;177(4):865–880e821.CrossRefPubMed
9.
Shang A, Gu C, Wang W, Wang X, Sun J, Zeng B, Chen C, Chang W, Ping Y, Ji P, et al. Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p- TGF-beta1 axis. Mol Cancer. 2020;19(1):117.CrossRefPubMedPubMedCentral
10.
Xu YX, Pu SD, Li X, Yu ZW, Zhang YT, Tong XW, Shan YY, Gao XY. Exosomal ncRNAs: novel therapeutic target and biomarker for diabetic complications. Pharmacol Res. 2022;178:106135.CrossRefPubMed
11.
Li X, Shen M. Circular RNA hsa_circ_103809 suppresses hepatocellular carcinoma proliferation and invasion by sponging miR-620. Eur Rev Med Pharmacol Sci. 2019;23(2):555–66.PubMed
12.
Huang G, Liang M, Liu H, Huang J, Li P, Wang C, Zhang Y, Lin Y, Jiang X. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/beta-catenin pathway. Cell Death Dis. 2020;11(12):1065.CrossRefPubMedPubMedCentral
13.
14.
Wang J, Liu Q, Shyr Y. Dysregulated transcription across diverse cancer types reveals the importance of RNA-binding protein in carcinogenesis. BMC Genomics. 2015;16(Suppl 7):5.CrossRef
15.
16.
Ren L, Fang X, Shrestha SM, Ji Q, Ye H, Liang Y, Liu Y, Feng Y, Dong J, Shi R. LncRNA SNHG16 promotes development of oesophageal squamous cell carcinoma by interacting with EIF4A3 and modulating RhoU mRNA stability. Cell Mol Biol Lett. 2022;27(1):89.CrossRefPubMedPubMedCentral
17.
Lin Y, Zhang J, Cai J, Liang R, Chen G, Qin G, Han X, Yuan C, Liu Z, Li Y, et al. Systematic analysis of Gene expression alteration and Co-expression Network of eukaryotic initiation factor 4A-3 in Cancer. J Cancer. 2018;9(24):4568–77.CrossRefPubMedPubMedCentral
18.
Jiang Z, Tai Q, Xie X, Hou Z, Liu W, Yu Z, Liang Z, Chen S. EIF4A3-induced circ_0084615 contributes to the progression of colorectal cancer via miR-599/ONECUT2 pathway. J Exp Clin Cancer Res. 2021;40(1):227.CrossRefPubMedPubMedCentral
19.
Mao S, Zhang W, Yang F, Guo Y, Wang H, Wu Y, Wang R, Maskey N, Zheng Z, Li C, et al. Hsa_circ_0004296 inhibits metastasis of prostate cancer by interacting with EIF4A3 to prevent nuclear export of ETS1 mRNA. J Exp Clin Cancer Res. 2021;40(1):336.CrossRefPubMedPubMedCentral
20.
Wang X, Chen M, Fang L. hsa_circ_0068631 promotes breast cancer progression through c-Myc by binding to EIF4A3. Mol Ther Nucleic Acids. 2021;26:122–34.CrossRefPubMedPubMedCentral
21.
Gong J, Du C, Sun N, Xiao X, Wu H. Circular RNA hsa_circ_0005397 promotes hepatocellular carcinoma progression by regulating the miR-326/PDK2 axis. J Gene Med. 2021;23(6):e3332.CrossRefPubMed
22.
Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34–42.CrossRefPubMed
23.
Meng X, Hu D, Zhang P, Chen Q, Chen M. CircFunBase: a database for functional circular RNAs. Database (Oxford) 2019, 2019.
24.
Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15(3):155–60.CrossRefPubMed
25.
Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: current status and future prospects. Front Immunol. 2021;12:765101.CrossRefPubMedPubMedCentral
26.
27.
Su YM, Liu W, Yan XL, Wang LJ, Liu M, Wang HW, Jin KM, Bao Q, Wang K, Li J, et al. Five-year survival post hepatectomy for colorectal liver metastases in a real-world Chinese cohort: recurrence patterns and prediction for potential cure. Cancer Med. 2023;12(8):9559–69.CrossRefPubMedPubMedCentral
28.
Force M, Park G, Chalikonda D, Roth C, Cohen M, Halegoua-DeMarzio D, Hann HW. Alpha-fetoprotein (AFP) and AFP-L3 is most useful in detection of recurrence of Hepatocellular Carcinoma in patients after tumor ablation and with Low AFP Level. Viruses 2022, 14(4).
29.
Wu M, Liu H, Liu Z, Liu C, Zhang A, Li N. Analysis of serum alpha-fetoprotein (AFP) and AFP-L3 levels by protein microarray. J Int Med Res. 2018;46(10):4297–305.CrossRefPubMedPubMedCentral
30.
Louis C, Leclerc D, Coulouarn C. Emerging roles of circular RNAs in liver cancer. JHEP Rep. 2022;4(2):100413.CrossRefPubMed
31.
Shen H, Liu B, Xu J, Zhang B, Wang Y, Shi L, Cai X. Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer. J Hematol Oncol. 2021;14(1):134.CrossRefPubMedPubMedCentral
32.
Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release. 2022;348:84–94.CrossRefPubMedPubMedCentral
33.
Qu S, Hao X, Song W, Niu K, Yang X, Zhang X, Shang R, Wang Q, Li H, Liu Z. Circular RNA circRHOT1 is upregulated and promotes cell proliferation and invasion in pancreatic cancer. Epigenomics. 2019;11(1):53–63.CrossRefPubMed
34.
Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.CrossRefPubMedADS
35.
Yang Q, Du WW, Wu N, Yang W, Awan FM, Fang L, Ma J, Li X, Zeng Y, Yang Z, et al. A circular RNA promotes tumorigenesis by inducing c-myc nuclear translocation. Cell Death Differ. 2017;24(9):1609–20.CrossRefPubMedPubMedCentral
36.
Zang J, Lu D, Xu A. The interaction of circRNAs and RNA binding proteins: an important part of circRNA maintenance and function. J Neurosci Res. 2020;98(1):87–97.CrossRefPubMed
37.
Jiang X, Guo S, Wang S, Zhang Y, Chen H, Wang Y, Liu R, Niu Y, Xu Y. EIF4A3-Induced circARHGAP29 promotes aerobic glycolysis in Docetaxel-resistant prostate Cancer through IGF2BP2/c-Myc/LDHA signaling. Cancer Res. 2022;82(5):831–45.CrossRefPubMed
38.
Hu B, Chen R, Jiang M, Xiong S, Liu X, Fu B. EIF4A3 serves as a prognostic and immunosuppressive microenvironment factor and inhibits cell apoptosis in bladder cancer. PeerJ. 2023;11:e15309.CrossRefPubMedPubMedCentral
39.
Yu W, Liang J, Fang T, Jiang J, Zhao R, Li R, Han J, Tian H. EIF4A3 acts on the PI3K-AKT-ERK1/2-P70S6K pathway through FLOT1 to Influence the Development of Lung Adenocarcinoma. Mol Cancer Res. 2023;21(7):713–25.CrossRefPubMedPubMedCentral
40.
Ji W, Wang Q, Yang J. LncRNA HOXD-AS1 promotes the metastasis of human hepatocellular carcinoma via modulating miR-326/SLC27A4. Cancer Cell Int. 2020;20:161.CrossRefPubMedPubMedCentral
41.
Huang X, Tan W, Liu Z, Fu X, Li Z, Lai S, Li Q, Zhong X, Qu F, Zhang H, et al. EIF4A3-induced circZFAND6 promotes breast cancer proliferation and metastasis through the miR-647/FASN axis. Life Sci. 2023;324:121745.CrossRefPubMed
42.
Liu Y, Song J, Zhang H, Liao Z, Liu F, Su C, Wang W, Han M, Zhang L, Zhu H, et al. EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway. J Exp Clin Cancer Res. 2022;41(1):164.CrossRefPubMedPubMedCentral
Metadata
Title
Hsa_circ_0005397 promotes hepatocellular carcinoma progression through EIF4A3
Authors
Liu-Xia Yuan
Mei Luo
Ruo-Yu Liu
Hui-Xuan Wang
Lin-Ling Ju
Feng Wang
Ya-Li Cao
Zhong-Cheng Wang
Lin Chen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11984-6

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Pretreatment multiparametric MRI radiomics-integrated clinical hematological biomarkers can predict early rapid metastasis in patients with nasopharyngeal carcinoma

Research

Real-world efficacy and safety of capecitabine with oxaliplatin in patients with advanced adenocarcinoma of the ampulla of Vater

Research

The association of HBV infection and head and neck cancer: a systematic review and meta-analysis

Research

Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells

Research

Cancer diagnosis after emergency presentations in people with mental health and substance use conditions: a national cohort study

Research

Transversal approach via a bladder neck and prostate combined longitudinal incision versus standard approach of robotic-assisted radical prostatectomy for localized prostate cancer: a retrospective analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits